Virtu KCG Holdings LLC trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 65.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,958 shares of the medical equipment provider’s stock after selling 20,747 shares during the period. Virtu KCG Holdings LLC’s holdings in Hologic were worth $497,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of HOLX. Commonwealth Bank of Australia boosted its stake in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 600 shares during the last quarter. Miles Capital Inc. acquired a new stake in Hologic in the 1st quarter worth about $206,000. Beck Mack & Oliver LLC acquired a new stake in Hologic in the 2nd quarter worth about $209,000. Notis McConarty Edward acquired a new stake in Hologic in the 2nd quarter worth about $213,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in Hologic in the 2nd quarter worth about $213,000. 96.38% of the stock is currently owned by hedge funds and other institutional investors.
HOLX has been the topic of a number of research analyst reports. Royal Bank Of Canada decreased their price target on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Barclays PLC cut their price objective on Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a report on Thursday, August 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $47.77.
In other Hologic news, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total value of $276,908.24. Following the completion of the sale, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The disclosure for this sale can be found here. Insiders sold 25,883 shares of company stock valued at $1,035,007 in the last ninety days. Insiders own 0.79% of the company’s stock.
Shares of Hologic, Inc. (HOLX) opened at 36.86 on Wednesday. The stock has a market capitalization of $10.34 billion, a P/E ratio of 13.73 and a beta of 0.91. The company’s 50 day moving average price is $37.73 and its 200 day moving average price is $42.02. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter in the previous year, the firm earned $0.51 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, equities analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.